MAKERS LABORATORIES LTD.

NSE : NABSE : 506919ISIN CODE : INE987A01010Industry : Pharmaceuticals & DrugsHouse : Ipca Laboratories
BSE145.00-2.3 (-1.56 %)
PREV CLOSE ( ) 147.30
OPEN PRICE ( ) 148.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 2663
TODAY'S LOW / HIGH ( )142.45 153.00
52 WK LOW / HIGH ( ) 94157
NSE
This Company is not listed in NSE
( in Million)
Select year
ParticularsMar2023Mar2022Mar2021
Profit Before Tax-8.39156.88NA
Adjustment56.5152.09NA
Changes In working Capital-109.6332.34NA
Cash Flow after changes in Working Capital-61.51241.32NA
Cash Flow from Operating Activities-86.20184.99NA
Cash Flow from Investing Activities12.53-217.92NA
Cash Flow from Financing Activities57.813.28NA
Net Cash Inflow / Outflow-15.86-29.65NA
Opening Cash & Cash Equivalents23.0952.73NA
Cash & Cash Equivalent on Amalgamation / Take over / MergerNANANA
Cash & Cash Equivalent of Subsidiaries under liquidationsNANANA
Translation adjustment on reserves / op cash balalces frgn subsidiariesNANANA
Effect of Foreign Exchange FluctuationsNANANA
Closing Cash & Cash Equivalent7.2223.09NA

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.